enGene Inc. Receives NRC-IRAP Contribution, Initiates Convertible Note Financing

VANCOUVER, BRITISH COLUMBIA, Jun 10 (MARKET WIRE) --
enGene Inc., a privately held biotechnology company developing an
innovative platform technology for the treatment of diseases including
diabetes and inflammatory bowel disease (IBD), announced today that it
has received a nonrepayable contribution of up to $419,509 from the
National Research Council of Canada Industrial Research Assistance
Program (NRC-IRAP). This contribution, in addition to both technical and
business oriented advisory services provided by NRC-IRAP, will enable the
company to achieve several key milestones in the path to human clinical
trials for its Gut-Epithelial cell Modification System (GEMS(TM)).

"We have made tremendous progress in the last year by achieving
significant large animal results in the insulin program for diabetes, and
in early diseased animal studies in the anti-inflammatory cytokine
program for IBD. The NRC-IRAP support, specifically slated for continued
development of the IBD program, is important in both its timing and level
of funding," commented Dr. Anthony Cheung, Chief Science Officer and
co-founder of enGene. "Over the course of enGene's history, NRC-IRAP has
played a key role in supporting the development of GEMS(TM). We are very
pleased to have their continued support, which has been instrumental in
promoting innovations in our research and enhancing our platform
nucleotide-delivery technology and product pipeline."

"As evidenced by the interest expressed by potential partners at last
month's BIO International Convention in Atlanta, the opportunities for
our GEMS(TM) platform are wide and diverse," said Eric A. Adams,
President and CEO of enGene. "We are now initiating a Convertible Note
financing, targeting both existing and new investors, to specifically
advance the core programs, to increase our internal manufacturing
know-how and to explore additional applications for this novel technology
via partnerships." Recruitment into the new financing begins immediately
and is expected to remain open through the summer.

About enGene Inc. and GEMS(TM)

enGene's GEMS(TM) technology utilizes the therapeutic protein production
capacity of existing, normal, healthy cells in the gastrointestinal tract
by delivering nucleotides in a novel non-viral vector. For
GEMS(TM)-Insulin, this means enabling the patients' own cells to produce
insulin in a regulated, meal-dependant fashion resulting in physiologic
control of blood glucose levels. For IBD, anti-inflammatory agents are
produced near the site of inflammation to restore health. Other potential
applications for GEMS(TM) include obesity, anemia and hemophilia as well
as animal health. Additional information is available at
www.engeneinc.com.

Contacts:
enGene Inc.
Eric A. Adams
CEO
(604) 221-4362 x230
(604) 221.4369 (FAX)
www.engeneinc.com

Copyright 2009, Market Wire, All rights reserved.

-0-